Eloxx Pharmaceuticals Inc
ELOX
Get informed when a big investor buys or sells
+ FollowMarket Cap$91.22M
Close$
$3.38
73.1% downside
Current Fair Value
73.1% downsideOvervalued by 73.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $91.22 Million |
|---|---|
| Enterprise Value | $84.85 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.39 |
| Beta | -24.6 |
| Outstanding Shares | 4,382,295 |
Return
| Return on Equity | 236.25% |
|---|---|
| Return on Assets | -210.71% |
| Return on Invested Capital | 224.78% |
Valuation & Multiples
| P/E Ratio | -2.07 |
|---|---|
| PEG | -45.81 |
| Price to Sales | - |
| Price to Book Ratio | 12.57 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.98 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-5.07
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Eloxx Pharmaceuticals Inc
CEO: Robert Ward